Cure My Disease

Don't miss your cure!

 Log in / Sign up

New screening strategy could speed diagnosis of inherited aldosteronism

NCT ID NCT07700888

Diagnosis Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study tests a new screening method to tell apart two causes of high blood pressure: a rare genetic condition called Glucocorticoid-Remediable Aldosteronism (GRA) and a more common adrenal tumor. The approach combines an overnight dexamethasone suppression test with detailed steroid measurements. Researchers aim to find clear cut-off points that could help doctors identify GRA without needing genetic testing first.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
1 mg overnight dexamethasone suppression test
What this could lead to
If successful, this screening strategy could provide a faster, cheaper way to identify Glucocorticoid-Remediable Aldosteronism, reducing the need for genetic testing in many patients.
What could go wrong
This is a small observational study, so the diagnostic cut-off points may not generalize to broader populations. The test may not perfectly distinguish all cases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

50 people

The number who actually took part.

Started

Mar 2025

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of 31 patients diagnosed with Primary Aldosteronism (PA), including 8 cases of genetically confirmed Glucocorticoid-Remediable Aldosteronism (GRA) and 23 cases of Aldosterone-Producing Adenoma (APA).

Ages

12 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients diagnosed with Primary Aldosteronism (PA) according to clinical biochemical screening standards. GRA Group: Genetically confirmed presence of the $CYP11B1/CYP11B2$ chimeric gene. APA group：The patient was diagnosed with PA and the adrenal imaging showed a typical adrenal adenoma on one side. The AVS or Ga68-Pentixafor PET/CT indicated that the adrenal gland on the adenoma side had a dominant secretion of aldosterone. And any of the following conditions was met: (1) The postoperative pathology clearly confirmed an adrenal cortical adenoma, with immunohistochemistry showing aldosterone synthase CYP11B2 (+). (2) After unilateral adrenal resection, the biochemical results of the patient were completely relieved, meeting the surgical outcome criteria for PA. Exclusion Criteria: * Exclude patients with secondary hypertension caused by other reasons (such as Cushing's syndrome, pheochromocytoma), severe cardiac and renal insufficiency (eGFR \< 30 mL/min/1.73m²), or those who are unable to cooperate to complete the trial process for various reasons.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glucocorticoid-remediable aldosteronism are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aldosterone-producing adrenal cortex adenoma glucocorticoid-remediable aldosteronism hyperaldosteronism primary aldosteronism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Primary aldosteronism Primary aldosteronism due to aldosterone producing adenoma

Contacts and locations

Locations

  • Peking Union Medical Colledge Hospital

    Beijing, 李泽文, 456350, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.